Press release
Castle Biosciences’ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as “Posters of Distinction” by the American Gastroenterological Association (AGA) Institute Council
New data demonstrate the risk-stratification performance and potential of the TissueCypher® Barrett’s Esophagus test to guide risk-aligned patient care
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"\nNew data demonstrate the risk-stratification performance and potential of the TissueCypher® Barrett’s Esophagus test to guide risk-aligned patient care decisions\n\n\n FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its three posters at the recent DDW Annual Meeting were honored as “Posters of Distinction” by the AGA Institute Council, ranking among the top 10% of the more than 3,100 abstracts showcased during the meeting.\n\n\n“We are incredibly proud that all three of our posters presented at the recent DDW Annual Meeting received 'Poster of Distinction' honors,” said Robert Cook, Ph.D., senior vice president of research and development at Castle Biosciences. “We believe this signifies the value of our TissueCypher test in providing objective risk-stratification that can inform improved management decisions for patients with Barrett’s esophagus (BE).”\n\n\nFollowing are highlights of Castle’s “Posters of Distinction” at DDW 2023. Full-text abstracts will be published in the May online supplement to Gastroenterology; the posters are available on the DDW ePosters site under Posters of Distinction category, Esophageal Diseases.\n\n\nPoster # Tu1272: A Tissue Systems Pathology Test Objectively Risk-Stratifies Patients with Barrett’s Esophagus: Results from a Multicenter U.S. Clinical Experience\nPresenter: Study Author, Michael Yodice, M.D., Geisinger Health\n\n\nTissueCypher test results from 2,456 BE patients ordered by 273 physicians at 32 academic centers and 161 community centers between June 2016 and October 2022 were evaluated in the study. TissueCypher risk-stratified patients in each pathologic (non-dysplastic BE (NDBE), indefinite for dysplasia (IND) and low-grade dysplasia (LGD)) and clinicopathologic (females, males, short-segment BE and long-segment BE) subset. Intermediate-risk TissueCypher scores in NDBE patients predicted a five-year risk of progression to high-grade dysplasia (HGD)/esophageal adenocarcinoma (EAC) of 6.2%, which was similar to the progression risk of 4.8% in patients with LGD in this community-based cohort, as well as published estimates. High-risk TissueCypher scores in NDBE patients predicted a five-year progression risk of 9.9%, which is higher than published estima...